The changing epidemiology of liver disease in HIV patients.

Abstract

Liver disease continues to be one of the leading causes of hospitalization and death in HIV-infected individuals. Important etiologies include both alcoholic and non-alcoholic steatohepatitis, and coinfection with hepatitis viruses B and C. While non-alcoholic fatty liver disease is increasingly diagnosed in this population, most cases of chronic hepatitis B can be well controlled with tenofovir-based regimens, and hepatitis C has entered a revolutionary era in which most patients may be cured with direct-acting antivirals. However, important gaps remain unaddressed. Hepatitis delta is a neglected disease, despite 15 million people being infected worldwide, and represents the most severe form of viral hepatitis. Hepatitis E is largely unrecognized, despite being the major cause of acute viral hepatitis worldwide and occasionally leading to chronicity in immunosuppressed individuals.

• Authors: Vincent Soriano, Pablo Barreiro, Kenneth E Sherman
• Journal: AIDS reviews (AIDS Rev) 2013 Jan-Mar Vol. 15 Issue 1 Pg. 25-31 ISSN: 1698-6997 [Electronic] Spain
• PMID: 23449226 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Anti-HIV Agents
• Antiviral Agents

Topics

• AIDS-Related Opportunistic Infections (drug therapy, epidemiology, immunology)
• Anti-HIV Agents (therapeutic use)
• Antiviral Agents (therapeutic use)
• Coinfection
• Disease Progression
• End Stage Liver Disease (drug therapy, epidemiology, immunology)
• Fatty Liver (drug therapy, epidemiology, immunology)
• Female
• HIV Infections (drug therapy, epidemiology, immunology)
• Hepatitis B (epidemiology)
• Hepatitis C (epidemiology)
• Hepatitis D (epidemiology)
• Hepatitis, Viral, Human (drug therapy, epidemiology, immunology)
• Humans
• Immunocompromised Host
• Male